Adicet Bio ACET
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Adicet Bio (ACET)
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Key Insights
Critical company metrics and information
Latest Closing Price
$0.7961Market Cap
$65.60 MillionPrice-Earnings Ratio
-0.60Total Outstanding Shares
82.40 Million SharesTotal Employees
143Dividend
No dividendIPO Date
September 16, 2020SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
131 dartmouth street, Boston, MA, 02116Homepage
https://www.adicetbio.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $111.31 Million |
| Net Cash Flow | $-100.31 Million |
| Net Cash Flow From Financing Activities, Continuing | $111.31 Million |
| Net Cash Flow From Investing Activities, Continuing | $-119.24 Million |
| Net Cash Flow, Continuing | $-100.31 Million |
| Net Cash Flow From Operating Activities | $-92.38 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss | $-117.12 Million |
| Basic Earnings Per Share | $-1.33 |
| Interest Expense, Operating | $4,000 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Diluted Earnings Per Share | $-1.33 |
| Operating Expenses | $127.61 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $16,000 |
| Comprehensive Income/Loss | $-117.11 Million |
| Comprehensive Income/Loss Attributable To Parent | $-117.11 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Fixed Assets | $22.52 Million |
| Other Non-current Assets | $17.56 Million |
| Assets | $220.22 Million |
| Equity Attributable To Parent | $186.61 Million |
| Other Current Liabilities | $7.45 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ACET from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.